Skip to main content
SpringerLink
Log in

Locally Advanced Breast Cancer

  • Chapter
Oncologic Breast Surgery

Part of the book series: Updates in Surgery ((UPDATESSURG))

  • 1676 Accesses

Abstract

Locally advanced breast cancer (LABC) has been the usual clinical presentation in the past and still accounts for a sizable number of breast cancer cases in developing countries or in medically underserved populations of western countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Edge SB, Byrd DR, Compton CC et al (eds) (2010) American Joint Committee on Cancer Staging Manual (7th Edn), Springer, New York

    Google Scholar 

  2. Lee MC, Newman LA (2007) Management of patients with locally advanced breast cancer. Surg Clin N Am 87:379–398

    Article  PubMed  Google Scholar 

  3. Giordano SH (2003) Update on locally advanced breast cancer. The Oncologist 8:521–530

    Article  PubMed  Google Scholar 

  4. Hance KW, Anderson WF, Devesa SS et al (2005) Trends in inflammatory breast carcinoma incidence and survival: The surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97:966–975

    Article  PubMed Central  PubMed  Google Scholar 

  5. Haagensen CD, Stout AP (1943) Carcinoma of the breast. Ann Surg 118:859–870

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. Rustogi A, Budrukkar A, Dinshaw K et al (2005) Management of locally advanced breast cancer: evolution and current practice. J Cancer Res Ther 1:21–30

    Article  PubMed  Google Scholar 

  7. Ragaz J, Olivotto IA, Spinelli JJ et al (2005) Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116–126

    Article  PubMed  Google Scholar 

  8. Overgaard M, Jansen MB, Overgaard J et al (1999) Postoperative therapy in high risk post menopausal breast cancer patients given adjuvant Tamoxifen. Danish Breast Cancer Cooperative Group 82c randomized trial. Lancet 353:1641–1648

    Article  CAS  PubMed  Google Scholar 

  9. Katz A, Strom EA, Buchholz TA et al (2000) Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 18:2817–2827

    CAS  PubMed  Google Scholar 

  10. Smith IC, Heys SD, Hutcheon AW et al (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 20:1456–1466

    Article  CAS  PubMed  Google Scholar 

  11. Truong PT, Olivotto IA, Kader HA et al (2005) Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 61:1337–1347

    Article  PubMed  Google Scholar 

  12. Anonymous edits.: RadiationOncology/Breast/Postmastectomy source: http://en.wikibooks.org/ w/indexphp?oklid=2474471

    Google Scholar 

  13. Yu Jb, Wilson LD, Dasgupta T et al (2008) Postmastectomy radiation therapy for lymph nodenegative, locally advanced breast cancer after modified radical mastectomy: analysis of the NCI Surveillance, Epidemiology and End Results database. Cancer 11:38–47

    Article  Google Scholar 

  14. Jagsi R, Abi Raad R, Goldberg S et al (2005) Locoregional recurrence rates and prognostic factors for failure in node negative patients treated with mastectomy: implications for postmastectomy radiation. Int J Radiat Onco Biol Phys 62:1035–1039

    Article  Google Scholar 

  15. Mamounas EP, Anderson SJ, Dignam JJ et al (2012) Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 30:3960–3966

    Article  PubMed Central  PubMed  Google Scholar 

  16. Buchholz TA, Katz A, Strom EA et al (2002) Pathologic tumor size and lymph node status predict for different rates of locoregional recurrence after mastectomy for breast cancer patients treated with neoadjuvant versus adjuvant chemotherapy. Int J Radiat Oncol Biol Phys 53:880–888

    Article  PubMed  Google Scholar 

  17. Rajagopalan MS, Sushil Beriwal S, Shinde A et al (2012) Recommendationsfor Post Mastectomy Radiation Therapy After Neoadjuvant Chemotherapy: An International Survey of Radiation Oncologists. American Radium Society 94th annual Meeting, Las Vegas

    Google Scholar 

  18. Mauri D, Pavlidis N, Ioannidis JPA (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97:188–194

    Article  PubMed  Google Scholar 

  19. Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685

    CAS  PubMed  Google Scholar 

  20. Hortobagyi GN, Singletary SE, Strom EA (2004) Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M et al (eds) Disease of the breast, 3rd edn. LWW, Philadelphia, pp 951–969

    Google Scholar 

  21. Untch M, von Minckwitz G (2009) Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res 11:203–209

    Article  PubMed Central  PubMed  Google Scholar 

  22. Bear HD, Anderson S, Brown A et al (2003) The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from NSABBP B-27. J Clin Oncol 21:4165–4174

    Article  CAS  PubMed  Google Scholar 

  23. Taucher S, Steger GG, Jakesz R et al (2008) The potential risk of neoadjuvant chemotherapy in breast cancer patients-results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07). Breast Cancer Res Treat 112:309–316

    Article  CAS  PubMed  Google Scholar 

  24. Mieog JS, van der Hage JA, van de Velde CJH (2007) Preoperative chemotherapy for women with operable breast cancer. Cochrane database of syst rev 2:CD005002

    Google Scholar 

  25. Mauriac L, MacGrogan G, Avril A et al (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median followup. Ann Oncol 10:47–52

    Article  CAS  PubMed  Google Scholar 

  26. Scholl SM, Pierga JA, Asselain B et al (1995) Breast tumor response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer 31A:1969–75

    Article  CAS  PubMed  Google Scholar 

  27. Makris A, Powles TJ, Ashley SE et al (1998) A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 9:1179–1184

    Article  CAS  PubMed  Google Scholar 

  28. Van der Hage JA, van de Velde CJ, Julien JP et al (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19:4224–4237

    PubMed  Google Scholar 

  29. Bonadonna G, Veronesi U, Brambilla C et al (1990) Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more. J Natl Cancer Inst 82:1539–1545

    Article  CAS  PubMed  Google Scholar 

  30. Penault-Llorca F, Abrial C, Mouret Reynier MA et al (2007) Achieving higher pathological complete response rates in HER-2-positive patients with induction chemotherapy without trastuzumab in operable breast cancer. Oncologist 12:390–396

    Article  CAS  PubMed  Google Scholar 

  31. Swain SM, Sorace RA, Bagley CS et al (1987) Neoadjuvant chemotherapy in the combined approach of locally advanced nonmetastatic breast cancer. Cancer Res 47:3889–3894

    CAS  PubMed  Google Scholar 

  32. Semiglazov VF, Topuzov EE, Bavli JL et al (1994) Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage IIb-IIIa breast cancer. Ann Oncol 5:591–595

    CAS  PubMed  Google Scholar 

  33. Estévez LG, Cuevas JM, Anton A et al (2003) Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer. Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study. Clin Cancer Res 9:686–692

    PubMed  Google Scholar 

  34. Alvarez A, Rodger J, Brosio C et al (2002) Neoadjuvant chemotherapy for stage III breast cancer: Does the addition of paclitaxel to doxorubicin increase complete response-A single institution non-randomized study. Eur J Cancer.38:S73

    Article  Google Scholar 

  35. Gianni L, Baselga J, Eiermann N et al (2002) First report of the european Cooperative Trial in operable breast cancer (ECTO): effects of primary systemic therapy on local-regional disease. Proc ASCO 21:34a (Abstr. 132).

    Google Scholar 

  36. Yao X, Hosenpud J, Chitambar CR et al (2012) A Phase II study of concurrent docetaxel, epirubicin and cyclophosphamide as a neoadjuvant chemotherapy regimen in patients with locally advanced breast cancer. J Cancer 3:145–151. doi:10.7150/jca.3980

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  37. Buzdar AU, Singletary SE, Theriault SR et al (1999) Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. JCO 17:3412–3417

    CAS  Google Scholar 

  38. Coudert BP, Arnould L, Moreau L et al (2006) Preoperative systemic (neoadjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: results of a multicenter phase II trial. Ann Oncol 17:409–414

    Article  CAS  PubMed  Google Scholar 

  39. Buzdar AU, Valero V, Ibrahim NK et al (2007) Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res. 13:228

    Article  CAS  PubMed  Google Scholar 

  40. Cristofanilli M, Buzdar AU, Hortobagyi GN (2003) Update on the management of inflammatory breast cancer. The Oncologist 8:141–148

    Article  CAS  PubMed  Google Scholar 

  41. Green MC, Buzdar AU, Smith T et al (2005) Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23:5983–5992

    Article  CAS  PubMed  Google Scholar 

  42. Provenzano E, Vallier AL, Champ R et al (2013) A central review of histopathology reports after breast cancer neoadjuvant chemotherapy in the neo-tango trial. Br J Cancer doi: 10.1038/bjc.2012.547

    Google Scholar 

  43. VonMinckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 30:1796–1804

    Article  Google Scholar 

  44. Kaufmann M, Hortobagyi GN, Goldhirsch A et al (2006) Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. J Clin Oncol 24:1940–1949

    Article  PubMed  Google Scholar 

  45. Kling KM, Ostrzega N, Schmit P (1997) Breast conservation after induction chemotherapyfor locally advanced breast cancer. Am Surg. 63:861–864

    CAS  PubMed  Google Scholar 

  46. Onesti JK, Mangus BE, Helmer SD et al (2008) Breast cancer tumor size: correlation between magnetic resonance imaging and pathology measurements. Am J Surg 196:844–848

    Article  PubMed  Google Scholar 

  47. Abraham D, Jones R, Jones S et al (1996) Evaluation of neoadjuvant chemotherapeutic response and locally advanced breast cancer by magnetic resonance imaging. Cancer 78:91–100

    Article  CAS  PubMed  Google Scholar 

  48. Bellon JR, Livingston RB, Eubank WB et al (2004) Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol 27:407–410

    Article  PubMed  Google Scholar 

  49. Singletary SE, McNeese MD, Hortobagyi GN (1992) Feasibility of breast conservation surgery after induction chemotherapy for locally advanced breast cancer. Cancer 69:2849–2852

    Article  CAS  PubMed  Google Scholar 

  50. Myers RE, Johnston M, Pritchard K et al (2001) Baseline staging tests in primary breast cancer: a practice guideline. CMAJ 164:1439–1444

    CAS  PubMed Central  PubMed  Google Scholar 

  51. Nakamura S, Ishiyama M, Tsunoda-Shimizu H et al (2007) Magnetic resonance mammography has limited ability to estimate pathological complete remission after primary chemotherapy or radiofrequency ablation therapy. Breast Cancer. 14:123–130

    Article  PubMed  Google Scholar 

  52. Schwarz-Dose J, Untch M, Tiling R et al (2009) Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F] fluorodeoxyglucose. J Clin Oncol 27:535–541

    Article  PubMed  Google Scholar 

  53. Holland R, Veling SH, Mravunav M et al (1985) Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer 56:979–990

    Article  CAS  PubMed  Google Scholar 

  54. Clouth B, Chandrasekharan S, Inwang R et al (2007) The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer. Eur J Surg Oncol 33:961–966

    Article  CAS  PubMed  Google Scholar 

  55. American Society of Plastic Surgeons (2010) 2009 Reconstructive Breast Procedures, In: American Society of Plastic Surgeons, September 13, 2011, Available from http://www.plasticsurgery. org/Documents/news-resources/statistics/2009-statistics/2009breast reconsurgery.pdf

    Google Scholar 

  56. Adams WP Jr (2009) Capsular contracture: What is it? What causes it? How can it be prevented and managed? Clinics in Plastic Surgery 36:119–126

    Article  PubMed  Google Scholar 

  57. Huges K, Brown C, Perez V et al (2012) The effect of radiotherapy on implant-based breast reconstruction in the setting of skin-sparing mastectomy: clinical series and review of complications. Anticancer Research 32:553–557

    Google Scholar 

  58. Salzberg CA, Ashikari AY, Koch RM, Chabner-Thompson E (2011) An 8-year experience of direct-to-implant immediate breast reconstruction using human acellular dermal matrix (AlloDerm). Plastic and Reconstructive Surgery 127:514–524

    Article  CAS  PubMed  Google Scholar 

  59. Salgarello M, Visconti G, Barone-Adesi L (2012) Fat grafting and breast reconstruction with implant: another option for irradiated breast cancer patients. Plast Reconstr Surg 129:317–329

    Article  CAS  PubMed  Google Scholar 

  60. Cordeiro PG, McCarthy CM (2006) A single surgeon’s 12-year experience with tissueexpander/implant breast reconstruction: p art II. An analysis of long-term complications, aesthetic outcomes, and patient satisfaction. Plastic and Reconstructive Surgery 118:832–839

    Article  CAS  PubMed  Google Scholar 

  61. Kronowitz SJ, Hunt KK, Kuerer HM et al (2004) Delayed-immediate breast reconstruction. Plast Reconstr Surg 113:1617–1628

    Article  PubMed  Google Scholar 

  62. Anderson WF, Schairer C, Chen BE et al (2005) Epidemiology of inflammatory breast cancer. Breast Dis 22:9–23

    PubMed Central  PubMed  Google Scholar 

  63. Robertson FM, Bondy M, Yang W et al (2010) Inflammatory breast cancer. The disease, the biology, the treatment. Ca Cancer J Clin 60:351–375

    Article  PubMed  Google Scholar 

  64. Dawood S, Merajver SD, Viens P et al (2011) International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22:515–523

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of General Surgery and Surgical Oncology, San Filippo Neri Hospital, Rome, Italy

    Stefano P. Drago

Authors
  1. Stefano P. Drago
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Battista Grassi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano P. Drago .

Editor information

Editors and Affiliations

  1. Department of Surgery Breast Surgery Unit, Ospedali Riuniti University Hospital, Ancona, Italy

    Carlo Mariotti

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Drago, S.P., Grassi, G.B. (2014). Locally Advanced Breast Cancer. In: Mariotti, C. (eds) Oncologic Breast Surgery. Updates in Surgery. Springer, Milano. https://doi.org/10.1007/978-88-470-5438-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-5438-7_12

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-5437-0

  • Online ISBN: 978-88-470-5438-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation